(RENE) ReNeuron Group
Summary
Trade long or short on this share now through an Interactive Investor Spread Bet or CFD
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||||||||||
| Headline | Source | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 20-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 9080V ReNeuron Group plc 20 January 2012
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 17-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 6569V ReNeuron Group plc 17 January 2012 For Immediate Release 17 January 2012
ReNeuron Group plc ("ReNeuron" or "the Company")
ReNeuron confirms webcast and content of its Stem Cell Technical Seminar Date: 17 January 2012
ReNeuron Group plc (AIM: RENE), a leading, UK-based stem cell company, is pleased to announce that it will host a live and recorded webcast of the previously announced Stem Cell Technical Seminar for analysts, investors and media to be held today, commencing at 10:00am (GMT).
Webcast Details
Running in parallel with the Stem Cell Technical Seminar will be a live webcast. Please log on 10 minutes before the start of the webcast at (10:00am GMT). The webcast log on address is: http://mediaserve.buchanan.uk.com/2012/reneuron170112/registration.asp
A recording of the webcast will also be made available on Buchanan's and ReNeuron's websites following the seminar. Details are as follows: For Buchanan: www.buchanan.uk.com. For ReNeuron: www.reneuron.com
ReNeuron's Stroke Clinical Trial
The seminar will include a progress report on the PISCES clinical trial of ReNeuron's ReN001 stem cell therapy for disabled stroke patients.The Company last provided an update on the study on 28 November, 2011. Since then, the second, fourth and fifth patients treated in the study have reached their twelve, three and one month follow-up points, respectively. There continue to be no cell-related adverse events reported in any of the patients treated to date and neurological and other safety assessments continue to show no deterioration in the health of any of the patients as a result of the ReN001 treatment.
The study's Principal Investigator, Glasgow University's ProfessorKeith Muir, presented a progress report with the PISCES clinical trialat the Stroke Association's 6th UK Stroke Forum Conference in Glasgow inlate November 2011. Professor Muir's presentation today will incorporate the information given in that earlier progress report and will take into account the further follow-up points reached since his last progress report, as detailed above.
A detailed agenda for the seminar is shown below.
ReNeuron Stem CellTechnical Seminar: 17 January 2012
PRELIMINARY AGENDA
10.00-10.15 Registration and coffee
10.15-10.25 Introduction Michael Hunt - Chief Executive Officer, ReNeuron
10.25-10.35 Stem cells - their potential as a new therapeutic paradigm Colin Blakemore FMedSciFRS - Professor of Neuroscience, Department of Physiology, Anatomy and Genetics, University of Oxford
10.35-10.45 Overview and advantages of ReNeuron's stem cell technologies Dr John Sinden - Chief Scientific Officer, ReNeuron
10.45-11.05 The PISCES clinical trial with ReN001 for stroke - a progress report Keith Muir - SINAPSE Professor of Clinical Imaging and Consultant Neurologist, Institute of Neuroscience and Psychology, University of Glasgow
11.05-11.15 Coffee break
11.15-11.30 Clinical development of ReN001 and ReNeuron's other cell-based therapies - opportunities and challenges Dr Mike McDonald - Clinical Development Consultant to ReNeuron
11.30-11.45 Manufacturing and scale-up of ReNeuron's cell-based therapies Dr Kenny Pollock - Head of Cell Development, ReNeuron
11.45-12.00 ReN009 for critical limb ischaemia - progress to date and future plans Dr Paul Stroemer - Programme Manager &Head of Pre-clinical Research, ReNeuron
12.00-12.15 ReN003 for retinitis pigmentosa - progress to date and future plans Dr Sara Patel - Programme Manager & Head of Toxicology, ReNeuron
12.15-12.30 Q&A
12.30-13.30 Buffet lunch
- Ends -
Enquiries:
Michael Hunt, Chief Executive Officer - ReNeuron +44 (0) 1483 302560 Dr John Sinden, Chief Scientific Officer - ReNeuron
Lisa Baderoon, Mark Court, Isabel Podda +44 (0) 20 7466 5000 Buchanan Communications
About ReNeuron ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 3799V ReNeuron Group plc 11 January 2012
Change of Adviser and Broker
ReNeuron Group plc (LSE: RENE.L) ("ReNeuron" or "the Company") announces the appointment of Cenkos Securities plc, as Nominated Adviser and Broker to the Company, with immediate effect.
Enquiries: ReNeuron Michael Hunt, Chief Executive Officer +44 (0) 1483 302560 Dr John Sinden, Chief Scientific Officer
Buchanan Communications Lisa Baderoon, Mark Court, Isabel Podda +44 (0) 20 7466 5000
About ReNeuron ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11-01-12 | RNS |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
RNS Number : 3376V ReNeuron Group plc 11 January 2012 PRESS RELEASE
New data demonstrate stability of ReNeuron's lead stem cell line in scale-up conditions
Guildford, UK, 11 January 2012: ReNeuron Group plc (LSE: RENE.L) ("ReNeuron" or "the Company") announces that its academic collaborators are presenting new data regarding the stability of the Company's lead CTX stem cell line in large-scale manufacturing conditions. The first clinical application for the CTX cell line is ReNeuron's ReN001 stem cell therapy for disabled stroke patients, currently in Phase I clinical development.
Professor Mike Hoare, Co-Director of The Advanced Centre for Biochemical Engineering at University College London (UCL), will present the results at the Scale-Up and Manufacturing of Cell-Based Therapies conference in San Diego, US, on 11-13 January 2012. The UCL team conducted studies with a number of cell candidates, including ReNeuron's CTX cell line. The results show that the CTX cells retained their morphology and growth characteristics when exposed to the levels of shear and centrifugal stresses that could be experienced in future large-scale manufacture of the cells for widespread clinical use.
The studies were conducted with the support of a grant from the UK Government's Technology Strategy Board and form part of a larger bioprocessing collaboration under the grant involving ReNeuron, UCL, Nottingham Trent University, LGC and others.
Dr John Sinden, Chief Scientific Officer of ReNeuron, commented:
"These new research results demonstrate the robust nature of ReNeuron's CTX cell line when subjected to manufacturing scale-up stresses and thus the potential of this cell line to form the basis of a cell-based therapeutic product for wide-scale clinical application. The ability to utilise ReNeuron's proprietary cell expansion technologies to readily manufacture our cell products at scale has always been a primary element in our product development strategy and one that we believe will pay off for the Company when we seek to license our therapies to commercial development partners in due course."
More details on the Scale-Up and Manufacturing of Cell-Based Therapies conference can be found at http://www.engconfintl.org/12at.html.
Enquiries:
Michael Hunt, Chief Executive Officer - ReNeuron +44 (0) 1483 302560 John Sinden, Chief Scientific Officer- ReNeuron
Lisa Baderoon, Mark Court, Isabel Podda +44 (0) 20 7466 5000 Buchanan Communications
David Hart +44 (0) 20 7776 6550 Daniel Stewart & Company plc
About ReNeuron ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. ReNeuron's lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development. The Company is also developing stem cell therapies for other conditions such as peripheral arterial disease, a serious and common side-effect of diabetes, and blindness-causing diseases of the retina.
ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell®products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Merck Millipore.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. This information is provided by RNS The company news service from the London Stock Exchange More |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
They have not been approved or issued by Interactive Investor Trading Limited.
Editor's Pick:
Glenstrata's just a silly word. Stick to big dividendsEditor's Pick:
Bulls should head for ChinaEditor's Pick:
Stock to Watch: Imperial TobaccoEditor's Pick:
George Godber’s AIM stock picks

